Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06136403 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

Study acronym: GENEPID
StatusRecruiting
PhasePhase 2
Started2024-03-18
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 5, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-07-31
Study Status, Contacts/Locations v5
Start date2023-03-18→2024-03-18
Study sites1→2
2025-02-21
Study Status, Oversight v4
Primary completion date2024-12-31→2025-09-30
Completion date2025-04-30→2026-10-12
2024-11-04
Study Status, Conditions v3
Re-verified, no change to tracked fields
2024-10-18
Not Yet Recruiting→Recruiting Study Status, Conditions, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2024-07-31→2024-12-31
Start dateestimated 2024-01-01→confirmed 2023-03-18
Study sites1 entry, revised
DRCICHU de Nice
2023-11-24
Study Status, Arms and Interventions v1
Interventionsdeucrvastatine (Drug)→deucravacitinib (Drug)
2023-11-13
Original filing
The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment. Participants will take treatments and have to use bullets during the study period.
Trial Details
NCT Number NCT06136403
Lead Sponsor Centre Hospitalier Universitaire de Nice
Conditions Epidermolysis Bullosa Simplex, Ichthyosis, Genodermatosis, Inflammatory Congenital Ichthyoses
Enrollment 10 participants
Start Date 2024-03-18
Primary Completion 2025-09-30 (estimated)
Study Completion 2026-10-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-05